All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors
- PMID: 20560996
- PMCID: PMC6493870
- DOI: 10.1111/j.1755-5949.2010.00162.x
All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors
Abstract
Background: The dopamine D2 receptor is the common target for antipsychotics, and the antipsychotic clinical doses correlate with their affinities for this receptor. Antipsychotics quickly enter the brain to occupy 60-80% of brain D2 receptors in patients (the agonist aripiprazole occupies up to 90%), with most clinical improvement occurring within a few days. The D2 receptor can exist in a state of high-affinity (D2(High) ) or in a state of low-affinity for dopamine (D2Low).
Aim: The present aim is to review why individuals with schizophrenia are generally supersensitive to dopamine-like drugs such as amphetamine or methyphenidate, and whether the D2(High) state is a common basis for dopamine supersensitivity in the animal models of schizophrenia.
Results: All animal models of schizophrenia reveal elevations in D2(High) receptors. These models include brain lesions, sensitization by drugs (amphetamine, phencyclidine, cocaine, corticosterone), birth injury, social isolation, and gene deletions in pathways for NMDA, dopamine, GABA, acetylcholine, and norepinephrine.
Conclusions: These multiple abnormal pathways converge to a final common pathway of dopamine supersensitivity and elevated D2(High) receptors, presumably responsible for psychotic symptoms. Although antipsychotics alleviate psychosis and reverse the elevation of D2(High) receptors, long-term antipsychotics can further enhance dopamine supersensitivity in patients. Therefore, switching from a traditional antipsychotic to an agonist antipsychotic (aripiprazole) can result in psychotic signs and symptoms. Clozapine and quetiapine do not elicit parkinsonism or tardive dyskinesia because they are released from D2 within 12 to 24 h. Traditional antipsychotics remain attached to D2 receptors for days, preventing relapse, but allowing accumulation that can lead to tardive dyskinesia. Future goals include imaging D2(High) receptors and desensitizing them in early-stage psychosis.
Conflict of interest statement
The author is also affiliated with Clera, Inc., a pharmaceutical company, but has no other competing interests.
Figures







Similar articles
-
Dopamine D2 receptors as treatment targets in schizophrenia.Clin Schizophr Relat Psychoses. 2010 Apr;4(1):56-73. doi: 10.3371/CSRP.4.1.5. Clin Schizophr Relat Psychoses. 2010. PMID: 20643630 Review.
-
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.Psychother Psychosom. 2017;86(4):189-219. doi: 10.1159/000477313. Epub 2017 Jun 24. Psychother Psychosom. 2017. PMID: 28647739 Review.
-
Psychosis pathways converge via D2high dopamine receptors.Synapse. 2006 Sep 15;60(4):319-46. doi: 10.1002/syn.20303. Synapse. 2006. PMID: 16786561 Review.
-
Schizophrenia and dopamine receptors.Eur Neuropsychopharmacol. 2013 Sep;23(9):999-1009. doi: 10.1016/j.euroneuro.2013.06.005. Epub 2013 Jul 13. Eur Neuropsychopharmacol. 2013. PMID: 23860356 Review.
-
Atypical antipsychotics: mechanism of action.Can J Psychiatry. 2002 Feb;47(1):27-38. Can J Psychiatry. 2002. PMID: 11873706 Review.
Cited by
-
Synapsin II gene expression in the dorsolateral prefrontal cortex of brain specimens from patients with schizophrenia and bipolar disorder: effect of lifetime intake of antipsychotic drugs.Pharmacogenomics J. 2014 Feb;14(1):63-9. doi: 10.1038/tpj.2013.6. Epub 2013 Mar 26. Pharmacogenomics J. 2014. PMID: 23529008 Free PMC article.
-
Tetraspanin (TSP-17) protects dopaminergic neurons against 6-OHDA-induced neurodegeneration in C. elegans.PLoS Genet. 2014 Dec 4;10(12):e1004767. doi: 10.1371/journal.pgen.1004767. eCollection 2014 Dec. PLoS Genet. 2014. PMID: 25474638 Free PMC article.
-
Improving target assessment in biomedical research: the GOT-IT recommendations.Nat Rev Drug Discov. 2021 Jan;20(1):64-81. doi: 10.1038/s41573-020-0087-3. Epub 2020 Nov 16. Nat Rev Drug Discov. 2021. PMID: 33199880 Free PMC article. Review.
-
Gaps or links between hormonal therapy and schizophrenia? (Review).Exp Ther Med. 2020 Oct;20(4):3508-3512. doi: 10.3892/etm.2020.9017. Epub 2020 Jul 16. Exp Ther Med. 2020. PMID: 32905106 Free PMC article. Review.
-
Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia.Med Hypotheses. 2015 Oct;85(4):391-6. doi: 10.1016/j.mehy.2015.06.011. Epub 2015 Jun 24. Med Hypotheses. 2015. PMID: 26118462 Free PMC article.
References
-
- Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 1987;91:415–433. - PubMed
-
- Curran C, Byrappa N, McBride A. Stimulant psychosis: Systematic review. Brit J Psychiat 2004;185:196–204. - PubMed
-
- Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review. J Cereb Blood Flow Metab 2000;20:423–451. - PubMed
-
- Zemlan FP, Hirschowitz J, Garver DL. Relation of clinical symptoms to apomorphine‐stimulated growth hormone release in mood‐incongruent psychotic patients. Arch Gen Psychiat 1986;43:1162–1167. - PubMed
-
- Seeman P, Nam D, Ulpian C, Liu IS, Tallerico T. New dopamine receptor, D2Longer, with unique TG splice site, in human brain. Brain Res Mol Brain Res 2000;76:132–141. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical